Compound class:
Synthetic organic
Comment: RG7112 is a clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket. In cancer cells expressing wild-type p53, this compound stabilizes it and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumour xenografts [2].
|
|
Immunopharmacology Comments |
Human macrophages integrate signals through p53 and NF-κB to drive proinflammatory cytokine induction and NF-κB is prominent in macrophage-initiated inflammatory responses. Therefore compounds activating p53, including indirectly via MMD2 as p53-activating chemotherapeutics acting upon p53-sufficient macrophages and precursor monocytes, may indirectly impact tumors lacking functional p53 [1] |